Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials.

ABSTRACT: The treatment of malignant melanoma has drastically changed over the past decade with the advent of immune checkpoint blockade, targeted therapy with BRAF/MEK inhibition, and other novel therapies such as oncolytic virus intralesional therapy. Despite improvements in patient response rates and survival with these new treatments, there exists a large portion of patients with surgically resectable disease that are high risk for relapse. Patients with high-risk resectable melanoma account for up to 20% of newly diagnosed cases. For this high-risk group of patients, neoadjuvant therapy has many purposed advantages over adjuvant therapy, including a more robust immune response due to abundant tumor antigens at treatment initiation, the ability to assess pathologic response to therapy, tumor dow

SUBMITTER: Witt RG 

PROVIDER: S-EPMC8894940 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature